Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aardvark Therapeutics, Inc. Common Stock (AARD)
USD6.44
+0.18 (+2.92%)
US NASDAQ Healthcare Biotechnology
Address
4370 La Jolla Village Drive 92122
San Diego, CA, US
San Diego, CA, US
CEO
Tien-Li Lee
Website
aardvarktherapeutics.com
IPO
2025-02-13
CIK 1774857 ISIN US0029421007
Description
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.44
+0.18 (+2.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
190.2K
Beta
3.93
Float Shares
10.86M
Free Float %
49.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.82% | +6.08% | +55.08% | -50.24% | -43.06% | -53.47% | -44.30% | -57.30% | -57.30% | -57.30% | -57.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
6.44
Low
6.00
-6.9%
Consensus
29.33
+355.2%
Median
35.00
+443.2%
High
47.00
+629.5%
DCF (Unlevered)
2.29
-64.4%
DCF (Levered)
2.38
-63.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 8 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
6.00
-6.9%
|
| Last Year | 5 |
26.00
+303.5%
|
| All Time | 6 |
26.50
+311.3%
|
Quality scores
Altman Z-Score
2.97
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-177.9% Q1'26: -130.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,317.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 5 Rev. Ana. 8 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
300.0K
300.0K – 300.0K
|
1.03M
1.03M – 1.03M
+242.0% YoY
|
8.46M
8.46M – 8.46M
+724.9% YoY
|
88.97M
88.97M – 88.97M
+951.2% YoY
|
277.72M
277.72M – 277.72M
+212.2% YoY
|
| EBITDA |
-22.65M
|
-62.73M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-22.67M
|
-62.73M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-20.59M
est: -36.86M (+44.1%)
|
-57.59M
est: -63.85M (+9.8%)
|
-77.88M
-97.53M – -58.33M
-22.0% YoY
|
-103.15M
-127.25M – -46.37M
-32.5% YoY
|
-132.67M
-144.06M – -32.81M
-28.6% YoY
|
-35.56M
-35.56M – -35.56M
+73.2% YoY
|
13.31M
13.31M – 13.31M
+137.4% YoY
|
| SGA |
5.31M
|
13.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.95
est: -2.86 (+66.7%)
|
-2.64
est: -2.93 (+9.9%)
|
-3.62
-4.47 – -2.67
-23.3% YoY
|
-3.36
-5.83 – -2.13
+7.1% YoY
|
-3.10
-6.60 – -1.50
+7.6% YoY
|
-1.63
-1.63 – -1.63
+47.4% YoY
|
0.61
0.61 – 0.61
+137.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
16
Total invested
880.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
16
-49 vs prev Q
New positions
5
Closed positions
54
Increased
11
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 476.6K +476.6K (+100.0%) | 6.26B +6.3B (+100.0%) | 2.19% +2.195 pp | 5.71% +5.713 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 2 | DECHENG CAPITAL LLC | 3.92M +— (+0.0%) | 51.41M -646.4K (-1.2%) | 18.04% -0.020 pp | 6.92% -2.167 pp | USD7.51 +74.8% | 4 qtrs — |
| 3 | CITADEL ADVISORS LLC | 1.29M -70.6K (-5.2%) | 16.92M -1.2M (-6.4%) | 5.94% -0.332 pp | 0.00% 0.000 pp | USD7.88 +66.6% | 4 qtrs — |
| 4 | LAURION CAPITAL MANAGEMENT LP | 1.01M -34.8K (-3.3%) | 13.32M -630.1K (-4.5%) | 4.67% -0.166 pp | 0.50% +0.256 pp | USD8.88 +47.9% | 4 qtrs — |
| 5 | BLACKROCK, INC. | 784.4K +475.0K (+153.5%) | 10.30M +6.2M (+150.3%) | 3.61% +2.186 pp | 0.00% +0.000 pp | USD13.11 +0.2% | 4 qtrs — |
| 6 | VANGUARD GROUP INC | 717.4K +161.7K (+29.1%) | 9.42M +2.0M (+27.5%) | 3.30% +0.742 pp | 0.00% +0.000 pp | USD12.02 +9.2% | 4 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 483.3K +163.7K (+51.2%) | 6.34M +2.1M (+49.3%) | 2.23% +0.752 pp | 0.00% +0.001 pp | USD13.24 -0.8% | 4 qtrs — |
| 8 | SILVERARC CAPITAL MANAGEMENT, LLC | 303.9K -3.0K (-1.0%) | 3.99M -89.7K (-2.2%) | 1.40% -0.015 pp | 0.55% +0.004 pp | USD11.16 +17.7% | 4 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 297.9K +103.8K (+53.5%) | 3.91M +1.3M (+51.6%) | 1.37% +0.477 pp | 0.00% +0.000 pp | USD12.14 +8.2% | 4 qtrs — |
| 10 | STATE STREET CORP | 158.2K +65.2K (+70.1%) | 2.08M +840.9K (+68.0%) | 0.73% +0.300 pp | 0.00% +0.000 pp | USD13.28 -1.1% | 3 qtrs — |
| 11 | TWO SIGMA INVESTMENTS, LP | 128.8K +65.2K (+102.6%) | 1.69M +845.5K (+100.1%) | 0.59% +0.300 pp | 0.00% +0.001 pp | USD13.21 -0.6% | 4 qtrs — |
| 12 | CENTIVA CAPITAL, LP | 97.5K +97.5K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.45% +0.449 pp | 0.01% +0.010 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 13 | CANTOR FITZGERALD, L. P. | 91.7K -5.0K (-5.2%) | 1.20M -81.6K (-6.3%) | 0.42% -0.024 pp | 0.02% +0.006 pp | USD9.33 +40.7% | 4 qtrs — |
| 14 | NORTHERN TRUST CORP | 89.3K +32.1K (+56.1%) | 1.17M +411.9K (+54.2%) | 0.41% +0.148 pp | 0.00% +0.000 pp | USD12.41 +5.8% | 4 qtrs — |
| 15 | MORGAN STANLEY | 78.0K +9.5K (+13.9%) | 1.02M +113.3K (+12.5%) | 0.36% +0.043 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 4 qtrs — |
| 16 | SUPERSTRING CAPITAL MANAGEMENT LP | 69.5K +69.5K (+100.0%) | 912.1K +912.1K (+100.0%) | 0.32% +0.320 pp | 0.49% +0.488 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 17 | GOLDMAN SACHS GROUP INC | 53.3K +34.4K (+181.9%) | 700.2K +448.7K (+178.4%) | 0.25% +0.158 pp | 0.00% +0.000 pp | USD11.17 +17.5% | 4 qtrs — |
| 18 | SCHONFELD STRATEGIC ADVISORS LLC | 50.1K -203.6K (-80.2%) | 658.0K -2.7M (-80.5%) | 0.23% -0.939 pp | 0.00% -0.016 pp | USD10.42 +26.0% | 4 qtrs — |
| 19 | PROPEL BIO MANAGEMENT, LLC | 46.4K +46.4K (+100.0%) | 609.1K +609.1K (+100.0%) | 0.21% +0.214 pp | 0.52% +0.520 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 20 | NUVEEN, LLC | 41.0K +41.0K (+100.0%) | 538.4K +538.4K (+100.0%) | 0.19% +0.189 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 21 | POINT72 ASSET MANAGEMENT, L.P. | 36.9K +36.9K (+100.0%) | 484.6K +484.6K (+100.0%) | 0.17% +0.170 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 22 | GSA CAPITAL PARTNERS LLP | 35.9K +35.9K (+100.0%) | 472.0K +472.0K (+100.0%) | 0.17% +0.165 pp | 0.04% +0.041 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 23 | JUMP FINANCIAL, LLC | 34.6K +34.6K (+100.0%) | 453.8K +453.8K (+100.0%) | 0.16% +0.159 pp | 0.01% +0.006 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 31.5K +17.3K (+121.4%) | 413.9K +224.6K (+118.7%) | 0.15% +0.080 pp | 0.00% +0.000 pp | USD13.31 -1.4% | 3 qtrs — |
| 25 | HRT FINANCIAL LP | 31.1K +31.1K (+100.0%) | 407.0K +407.0K (+100.0%) | 0.14% +0.143 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 26 | BANK OF AMERICA CORP /DE/ | 30.7K +6.7K (+28.1%) | 402.4K +84.4K (+26.5%) | 0.14% +0.031 pp | 0.00% +0.000 pp | USD12.41 +5.8% | 4 qtrs — |
| 27 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 27.0K +5.0K (+22.7%) | 354.4K +62.0K (+21.2%) | 0.12% +0.023 pp | 0.01% +0.001 pp | USD13.26 -1.0% | 2 qtrs — |
| 28 | UBS GROUP AG | 26.8K -27.9K (-51.0%) | 352.2K -375.1K (-51.6%) | 0.12% -0.129 pp | 0.00% 0.000 pp | USD11.89 +10.4% | 4 qtrs — |
| 29 | TWO SIGMA ADVISERS, LP | 26.2K +500.0 (+1.9%) | 343.9K +2.3K (+0.7%) | 0.12% +0.002 pp | 0.00% +0.000 pp | USD13.29 -1.2% | 2 qtrs — |
| 30 | XTX TOPCO LTD | 25.5K +25.5K (+100.0%) | 335.3K +335.3K (+100.0%) | 0.12% +0.118 pp | 0.01% +0.009 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 31 | BANK OF NEW YORK MELLON CORP | 22.4K +6.9K (+44.4%) | 294.2K +87.9K (+42.6%) | 0.10% +0.032 pp | 0.00% +0.000 pp | USD13.24 -0.8% | 2 qtrs — |
| 32 | BARCLAYS PLC | 20.5K -19.4K (-48.6%) | 269.3K -261.3K (-49.3%) | 0.09% -0.090 pp | 0.00% 0.000 pp | USD13.52 -2.9% | 3 qtrs — |
| 33 | DIAMETRIC CAPITAL, LP | 19.3K +19.3K (+100.0%) | 253.4K +253.4K (+100.0%) | 0.09% +0.089 pp | 0.07% +0.068 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 34 | ALPS ADVISORS INC | 17.9K +17.9K (+100.0%) | 234.6K +234.6K (+100.0%) | 0.08% +0.082 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 35 | TREXQUANT INVESTMENT LP | 16.8K +16.8K (+100.0%) | 221.1K +221.1K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.002 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 36 | LOS ANGELES CAPITAL MANAGEMENT LLC | 20.8K +20.8K (+100.0%) | 218.0K +218.0K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 37 | WALLEYE CAPITAL LLC | 16.0K +16.0K (+100.0%) | 210.6K +210.6K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 38 | DIADEMA PARTNERS LP | 15.9K +15.9K (+100.0%) | 208.5K +208.5K (+100.0%) | 0.07% +0.073 pp | 0.04% +0.036 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 39 | BNP PARIBAS ARBITRAGE, SNC | 15.9K -40.7K (-72.0%) | 208.1K -543.4K (-72.3%) | 0.07% -0.188 pp | 0.00% 0.000 pp | USD9.75 +34.7% | 4 qtrs — |
| 40 | WELLS FARGO & COMPANY/MN | 14.1K +10.2K (+259.5%) | 184.8K +132.7K (+255.0%) | 0.06% +0.047 pp | 0.00% +0.000 pp | USD13.23 -0.8% | 3 qtrs — |
| 41 | BALYASNY ASSET MANAGEMENT L.P. | 13.8K +13.8K (+100.0%) | 181.3K +181.3K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 42 | METLIFE INVESTMENT MANAGEMENT, LLC | 7.8K +7.8K (+100.0%) | 101.7K +101.7K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 43 | RHUMBLINE ADVISERS | 7.6K +1.8K (+32.4%) | 99.1K +23.3K (+30.8%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD13.42 -2.2% | 3 qtrs — |
| 44 | JPMORGAN CHASE & CO | 6.9K +4.6K (+197.2%) | 90.3K +59.6K (+193.5%) | 0.03% +0.021 pp | 0.00% +0.000 pp | USD11.24 +16.8% | 4 qtrs — |
| 45 | DEUTSCHE BANK AG\ | 6.4K +661.0 (+11.5%) | 83.8K +7.8K (+10.2%) | 0.03% +0.003 pp | 0.00% +0.000 pp | USD13.48 -2.6% | 3 qtrs — |
| 46 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 5.9K +3.3K (+129.4%) | 77.8K +43.5K (+126.5%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD13.30 -1.3% | 3 qtrs — |
| 47 | PERSISTENT ASSET PARTNERS LTD | 4.2K +4.2K (+100.0%) | 55.5K +55.5K (+100.0%) | 0.02% +0.020 pp | 0.02% +0.025 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 48 | NEW YORK STATE COMMON RETIREMENT FUND | 3.8K +— (+0.0%) | 50.2K -631.0 (-1.2%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD13.52 -2.9% | 3 qtrs — |
| 49 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 3.5K +3.5K (+100.0%) | 46.6K +46.6K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.004 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 50 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 2.1K +— (+0.0%) | 27.8K -350.0 (-1.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD13.29 -1.2% | 2 qtrs — |
| 51 | LEGAL & GENERAL GROUP PLC | 1.3K +701.0 (+119.4%) | 16.9K +9.1K (+116.7%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD13.31 -1.4% | 3 qtrs — |
| 52 | FMR LLC | 1.3K +893.0 (+246.0%) | 16.5K +11.7K (+241.7%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD13.18 -0.4% | 2 qtrs — |
| 53 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 1.1K +1.1K (+100.0%) | 13.9K +13.9K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 54 | STONE HOUSE INVESTMENT MANAGEMENT, LLC | 1.0K +— (+0.0%) | 13.1K -165.0 (-1.2%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD13.29 -1.2% | 2 qtrs — |
| 55 | CITIGROUP INC | 896.00 +729.0 (+436.5%) | 11.8K +9.5K (+429.7%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD13.20 -0.5% | 3 qtrs — |
| 56 | TOWER RESEARCH CAPITAL LLC (TRC) | 811.00 -374.0 (-31.6%) | 10.6K -5.1K (-32.4%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD13.52 -2.9% | 3 qtrs — |
| 57 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 784.00 +429.0 (+120.8%) | 10.3K +5.6K (+118.1%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD13.30 -1.3% | 3 qtrs — |
| 58 | ROYAL BANK OF CANADA | 599.00 +294.0 (+96.4%) | 9.0K +5.0K (+125.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD13.31 -1.4% | 3 qtrs — |
| 59 | AMERITAS INVESTMENT PARTNERS, INC. | 578.00 +— (+0.0%) | 7.6K -96.0 (-1.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.52 -2.9% | 3 qtrs — |
| 60 | LARSON FINANCIAL GROUP LLC | 506.00 +506.0 (+100.0%) | 6.6K +6.6K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 61 | RUSSELL INVESTMENTS GROUP, LTD. | 469.00 +— (+0.0%) | 6.2K -78.0 (-1.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.29 -1.2% | 2 qtrs — |
| 62 | GF FUND MANAGEMENT CO. LTD. | 427.00 +427.0 (+100.0%) | 5.6K +5.6K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD13.13 +0.0% | 1 qtrs NEW |
| 63 | AMALGAMATED BANK | 400.00 +207.0 (+107.3%) | 5.0K +2.0K (+66.7%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD13.32 -1.4% | 3 qtrs — |
| 64 | STERLING CAPITAL MANAGEMENT LLC | 345.00 +163.0 (+89.6%) | 4.5K +2.1K (+87.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD13.26 -1.0% | 3 qtrs — |
| 65 | EVERSOURCE WEALTH ADVISORS, LLC | 60.00 +— (+0.0%) | 788.00 -9.0 (-1.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.28 -1.1% | 2 qtrs — |
| 66 | CRESSET ASSET MANAGEMENT, LLC | — -141.8K (-100.0%) | — -1.9M (-100.0%) | 0.00% -0.654 pp | 0.00% -0.008 pp | USD— | 2 qtrs SOLD |
| 67 | JANE STREET GROUP, LLC | — -19.4K (-100.0%) | — -258.5K (-100.0%) | 0.00% -0.090 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 68 | STRS OHIO | — -1.1K (-100.0%) | — -14.6K (-100.0%) | 0.00% -0.005 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 69 | SRS CAPITAL ADVISORS, INC. | — -21.0 (-100.0%) | — -280.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 70 | ADAGE CAPITAL PARTNERS GP, L.L.C. | — -350.0K (-100.0%) | — -4.7M (-100.0%) | 0.00% -1.614 pp | 0.00% -0.007 pp | USD— | 4 qtrs SOLD |
| 71 | PNC FINANCIAL SERVICES GROUP, INC. | — -140.0 (-100.0%) | — -1.9K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 323.9K | 0.60% |
| 2 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 53.0K | 0.40% |
| 3 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 8.5K | 0.19% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 7.8K | 0.35% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.01% | 117.2K | 0.35% |
| 6 | iShares Biotechnology ETF IBB | 0.01% | 690.0K | 0.44% |
| 7 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 5.6K | 1.19% |
| 8 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 27.5K | 0.06% |
| 9 | Vanguard Russell 2000 ETF VTWO | 0.00% | 260.7K | 0.06% |
| 10 | Vanguard Russell 2000 Value ETF VTWV | 0.00% | 13.0K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
344.9K
Cash buys
—
Cash sales
—
Net activity
-344,949
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Sun Nelson | Officer | A-Award | D | Stock option (right to buy) | 70,549 | 13.48 | 951.0K | 70,549 | D | ↗ |
| 2026-02-09 | Lee Tien-Li | Director / Officer / 10% Owner | A-Award | D | Stock option (right to buy) | 203,851 | 13.48 | 2.75M | 203,851 | D | ↗ |
| 2026-02-09 | Jaiman Manasi | Officer | A-Award | D | Stock option (right to buy) | 70,549 | 13.48 | 951.0K | 70,549 | D | ↗ |
| 2025-12-11 | Sun Nelson | Officer | P-Purchase | A | Common Stock | 3,000 | 14.40 | 43.2K | 108,484 | D | ↗ |
| 2025-12-11 | Lee Tien-Li | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 7,000 | 14.49 | 101.4K | 1,551,613 | D | ↗ |
| 2025-10-15 | Lee Tien-Li | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 1,229 | 4.24 | 5.2K | 1,544,613 | D | ↗ |
| 2025-10-15 | Jones Bryan | Officer | M-Exempt | D | Stock option (right to buy) | 1,250 | 4.24 | 5.3K | 40,052 | D | ↗ |
| 2025-09-15 | Lee Tien-Li | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,500 | 9.94 | 34.8K | 1,543,384 | D | ↗ |
| 2025-09-12 | Lee Tien-Li | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 8.50 | 42.5K | 1,533,384 | D | ↗ |
| 2025-09-11 | Lee Tien-Li | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 6,000 | 7.82 | 46.9K | 1,528,384 | D | ↗ |
| 2025-09-10 | Lee Tien-Li | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 9,000 | 7.91 | 71.2K | 1,522,384 | D | ↗ |
| 2025-09-09 | Sun Nelson | Officer | P-Purchase | A | Common Stock | 6,000 | 8.07 | 48.4K | 105,484 | D | ↗ |
| 2025-08-28 | Lee Tien-Li | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 17,209 | 4.24 | 73.0K | 1,513,384 | D | ↗ |
| 2025-06-11 | Tong Victor Edward Jr | Director | A-Award | A | Stock Option (right to buy) | 61,017 | 11.29 | 688.9K | 61,017 | D | ↗ |
| 2025-06-11 | Sun Nelson | Officer | A-Award | A | Stock Option (right to buy) | 209,826 | 11.29 | 2.37M | 209,826 | D | ↗ |
| 2025-06-11 | Lee Tien-Li | Director / Officer / 10% Owner | A-Award | A | Stock option (right to buy) | 549,534 | 11.29 | 6.20M | 549,534 | D | ↗ |
| 2025-06-11 | Jones Bryan | Officer | A-Award | A | Stock Option (right to buy) | 122,033 | 11.29 | 1.38M | 122,033 | D | ↗ |
| 2025-06-11 | Jaiman Manasi | Officer | A-Award | A | Stock Option (right to buy) | 126,999 | 11.29 | 1.43M | 126,999 | D | ↗ |
| 2025-06-11 | Graf Susan E | Director | A-Award | A | Stock Option (right to buy) | 30,508 | 11.29 | 344.4K | 30,508 | D | ↗ |
| 2025-06-11 | Chi Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 61,017 | 11.29 | 688.9K | 61,017 | D | ↗ |
| 2025-06-11 | Baynes Roy D. | Director | A-Award | A | Stock Option (right to buy) | 30,508 | 11.29 | 344.4K | 30,508 | D | ↗ |
| 2007-08-17 | Creamer James W III | Officer | P-Purchase | A | Common | 500 | 1.90 | 950.00 | 50,800 | — | ↗ |
| 2007-03-06 | Zimlich Joseph C | Director | A-Award | A | Stock Option | 5,000 | 2.75 | 13.8K | 5,000 | — | ↗ |
| 2006-12-06 | Zimlich Joseph C | Director | P-Purchase | A | Common | 56,550 | 1.30 | 73.5K | 56,550 | — | ↗ |
| 2006-11-08 | Creamer James W III | Officer | P-Purchase | A | Stock Option | 100,000 | 1.65 | 165.0K | 100,000 | — | ↗ |
| 2006-10-26 | Zimlich Joseph C | Director | P-Purchase | A | Series A Convertible Preferred Stock | 17,000 | 3.00 | 51.0K | 17,000 | — | ↗ |
| 2006-05-12 | Creamer James W III | Officer | P-Purchase | A | Common Stock | 300 | 3.05 | 915.00 | 300 | — | ↗ |
| 2006-05-03 | Creamer James W III | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
21.82M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tien-Li Lee | Chief Executive Officer, Secretary & Director | 973.7K | — |
| Manasi Sinha Jaiman | Chief Medical Officer | 693.0K | — |
| Nelson Sun | CFO & COO | 603.3K | male |
| Bryan Jones | Chief Executive Officer of Ardia | 467.4K | — |
| Dvorit Samid | Executive Vice President of Medical Affairs | — | — |
| Justin T. Stege | VP and Head of Project Management & Strategy | — | male |
| Derrick C. Li | Chief Business Officer | — | male |
| Danny Villeneuve | Chief Commercial Officer | — | male |
| Ron Lewis | Vice President & Head of CMC | — | male |
| Terrie Kellmeyer | Senior Vice President of Regulatory Affairs | — | — |
| Christian Zapf | General Counsel | — | male |
| Timothy J. Kieffer | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AARD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
